201 related articles for article (PubMed ID: 35417944)
1. [Morphochemical study of alpha-synuclein, iron and iron-containing proteins in the substantia nigra of the brain in Parkinson's disease].
Salkov VN; Khudoerkov RM; Voronkov DN; Sobolev VB
Arkh Patol; 2022; 84(2):13-19. PubMed ID: 35417944
[TBL] [Abstract][Full Text] [Related]
2. Cell senescence induced by toxic interaction between α-synuclein and iron precedes nigral dopaminergic neuron loss in a mouse model of Parkinson's disease.
Shen QQ; Jv XH; Ma XZ; Li C; Liu L; Jia WT; Qu L; Chen LL; Xie JX
Acta Pharmacol Sin; 2024 Feb; 45(2):268-281. PubMed ID: 37674042
[TBL] [Abstract][Full Text] [Related]
3. [Lewy bodies in Parkinson's disease: histological, immunohistochemical, and interferometric examinations].
Voronkov DN; Salkov VN; Anufriev PL; Khudoerkov RM
Arkh Patol; 2018; 80(4):9-13. PubMed ID: 30059066
[TBL] [Abstract][Full Text] [Related]
4. Intranasal administration of α-synuclein preformed fibrils triggers microglial iron deposition in the substantia nigra of Macaca fascicularis.
Guo JJ; Yue F; Song DY; Bousset L; Liang X; Tang J; Yuan L; Li W; Melki R; Tang Y; Chan P; Guo C; Li JY
Cell Death Dis; 2021 Jan; 12(1):81. PubMed ID: 33441545
[TBL] [Abstract][Full Text] [Related]
5. [Morphochemical changes in the substantia nigra cellular structures in Parkinson's disease].
Salkov VN; Khudoerkov RM; Voronkov DN; Sobolev VB; Kutukova KA
Arkh Patol; 2017; 79(5):3-9. PubMed ID: 29027522
[TBL] [Abstract][Full Text] [Related]
6. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
7. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease.
Ferrer I; Martinez A; Blanco R; Dalfó E; Carmona M
J Neural Transm (Vienna); 2011 May; 118(5):821-39. PubMed ID: 20862500
[TBL] [Abstract][Full Text] [Related]
8. The role of alpha-synuclein as ferrireductase in neurodegeneration associated with Parkinson's disease.
Sian-Hulsmann J; Riederer P
J Neural Transm (Vienna); 2020 May; 127(5):749-754. PubMed ID: 32318880
[TBL] [Abstract][Full Text] [Related]
9. Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease.
Gründemann J; Schlaudraff F; Haeckel O; Liss B
Nucleic Acids Res; 2008 Apr; 36(7):e38. PubMed ID: 18332041
[TBL] [Abstract][Full Text] [Related]
10. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.
Dexter DT; Carayon A; Javoy-Agid F; Agid Y; Wells FR; Daniel SE; Lees AJ; Jenner P; Marsden CD
Brain; 1991 Aug; 114 ( Pt 4)():1953-75. PubMed ID: 1832073
[TBL] [Abstract][Full Text] [Related]
11. Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation.
Pal GD; Ouyang B; Serrano G; Shill HA; Goetz C; Stebbins G; Metman LV; Driver-Dunckley E; Mehta SH; Caviness JN; Sabbagh MN; Adler CH; Beach TG;
Mov Disord; 2017 Feb; 32(2):274-277. PubMed ID: 27911008
[TBL] [Abstract][Full Text] [Related]
12. Altered machinery of protein synthesis is region- and stage-dependent and is associated with α-synuclein oligomers in Parkinson's disease.
Garcia-Esparcia P; Hernández-Ortega K; Koneti A; Gil L; Delgado-Morales R; Castaño E; Carmona M; Ferrer I
Acta Neuropathol Commun; 2015 Dec; 3():76. PubMed ID: 26621506
[TBL] [Abstract][Full Text] [Related]
13. Alpha-synuclein modulates retinal iron homeostasis by facilitating the uptake of transferrin-bound iron: Implications for visual manifestations of Parkinson's disease.
Baksi S; Tripathi AK; Singh N
Free Radic Biol Med; 2016 Aug; 97():292-306. PubMed ID: 27343690
[TBL] [Abstract][Full Text] [Related]
14. Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation.
Tong J; Ang LC; Williams B; Furukawa Y; Fitzmaurice P; Guttman M; Boileau I; Hornykiewicz O; Kish SJ
Neurobiol Dis; 2015 Oct; 82():243-253. PubMed ID: 26102022
[TBL] [Abstract][Full Text] [Related]
15. Ferritinophagy and α-Synuclein: Pharmacological Targeting of Autophagy to Restore Iron Regulation in Parkinson's Disease.
Boag MK; Roberts A; Uversky VN; Ma L; Richardson DR; Pountney DL
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216492
[TBL] [Abstract][Full Text] [Related]
16. Variable expression of mitochondrial complex IV in the course of nigral intracellular accumulation of α-synuclein.
Lang A; Dassler E; Milenkovic I; Lutz MI; Kovacs GG
Parkinsonism Relat Disord; 2021 Sep; 90():57-61. PubMed ID: 34385008
[TBL] [Abstract][Full Text] [Related]
17. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels.
Gündner AL; Duran-Pacheco G; Zimmermann S; Ruf I; Moors T; Baumann K; Jagasia R; van de Berg WDJ; Kremer T
Neurobiol Dis; 2019 Jan; 121():205-213. PubMed ID: 30236861
[TBL] [Abstract][Full Text] [Related]
18. Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits.
Zhang J; Stanton DM; Nguyen XV; Liu M; Zhang Z; Gash D; Bing G
Neuroscience; 2005; 135(3):829-38. PubMed ID: 16165292
[TBL] [Abstract][Full Text] [Related]
19. [Ascendance of Abnormal α-synuclein Fibrils Through the Vagal Nerve in Parkinson's Disease].
Ohno K; Hirayama M
Brain Nerve; 2022 Aug; 74(8):979-984. PubMed ID: 35941794
[TBL] [Abstract][Full Text] [Related]
20. Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders.
Wise RM; Wagener A; Fietzek UM; Klopstock T; Mosharov EV; Zucca FA; Sulzer D; Zecca L; Burbulla LF
Neurobiol Dis; 2022 Dec; 175():105920. PubMed ID: 36351559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
